Business Context and Reporting Period
Company: Silexion Therapeutics Corp (SLXN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 15, 2026
Event: Entry into a Material Definitive Agreement (Inducement Offer Letter) to modify existing warrant terms and issue new warrants.
Key Financial Metrics and Transaction Details
This filing details a capital raise transaction rather than standard operating financial results. Key metrics include:
- Expected Gross Proceeds: Approximately $1.0 million from the exercise of existing warrants.
- Shares to be Issued (Existing Warrants): 1,995,092 ordinary shares.
- Reduced Exercise Price (Existing Warrants): $0.50 per share (reduced from original prices of $4.00 and $11.32).
- New Warrants Issued: 3,990,184 new warrants (Series C and Series D) to purchase ordinary shares.
- New Warrant Exercise Price: $0.50 per share.
- Placement Agent Fees: 7.0% cash fee plus 1.0% management fee on gross proceeds; additional 7.0% fee on future New Warrant exercises.
- Placement Agent Warrants: 139,656 warrants issued to the agent at an exercise price of $0.625 per share.
- Use of Proceeds: General corporate purposes.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the period. The material change is the restructuring of the company's warrant capitalization:
- Warrant Modification: Holders of 1,995,092 existing warrants (Series A, Series B, and Prior Inducement Warrants) agreed to exercise at a significantly reduced price of $0.50.
- Original Terms: The existing warrants previously had exercise prices of $4.00 (Series A and B) and $11.32 (Prior Inducement).
- Shareholder Approval: The transaction is subject to shareholder approval for the issuance of New Warrants.
Guidance, Outlook, Risks, and Contingencies
- Closing Date: Expected on or about May 18, 2026, subject to customary closing conditions.
- Registration Requirements: The Company must file a resale registration statement (Form S-3) within 30 days and seek effectiveness within 60 days (or 90 days if under full review).
- Lock-Up Provisions: The Company agreed not to issue ordinary shares or equivalents for 15 days post-closing and not to effect Variable Rate Transactions for one year post-closing.
- Liquidity Risk: There is no established trading market for the New Warrants, and the Company does not expect an active market to develop, resulting in extremely limited liquidity for these instruments.
- Forward-Looking Statements: The closing is not guaranteed and is subject to conditions; the Company disclaims any obligation to update these statements.
Important Facts for Investor Verification
- Verify the final closing date and whether the transaction closed as expected on May 18, 2026.
- Confirm shareholder approval status for the issuance of the 3,990,184 New Warrants.
- Monitor the effectiveness of the Resale Registration Statement (Form S-3) for the New Warrant Shares.
- Assess the dilution impact of the 1,995,092 shares issued immediately and the potential future issuance of 3,990,184 shares upon New Warrant exercise.
- Review the company's cash position post-transaction to ensure the ~$1.0 million net proceeds are sufficient for stated general corporate purposes.